PMID- 25275325
OWN - NLM
STAT- MEDLINE
DCOM- 20151222
LR  - 20211021
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 9
IP  - 10
DP  - 2014
TI  - Acylation stimulating protein, complement C3 and lipid metabolism in 
      ketosis-prone diabetic subjects.
PG  - e109237
LID - 10.1371/journal.pone.0109237 [doi]
LID - e109237
AB  - BACKGROUND: Ketosis-prone diabetes (KPDM) is new-onset diabetic ketoacidosis 
      without precipitating factors in non-type 1 diabetic patients; after management, 
      some are withdrawn from exogenous insulin, although determining factors remain 
      unclear. METHODS: Twenty KPDM patients and twelve type 1 diabetic patients 
      (T1DM), evaluated at baseline, 12 and 24 months with/without insulin maintenance 
      underwent a standardized mixed-meal tolerance test (MMTT) for 2 h. RESULTS: At 
      baseline, triglyceride and C3 were higher during MMTT in KPDM vs. T1DM (p<0.0001) 
      with no differences in non-esterified fatty acids (NEFA) while Acylation 
      Stimulating Protein (ASP) tended to be higher. Within 12 months, 11 KPDM were 
      withdrawn from insulin treatment (KPDM-ins), while 9 were maintained (KPDM+ins). 
      NEFA was lower in KPDM-ins vs. KPDM+ins at baseline (p = 0.0006), 12 months 
      (p<0.0001) and 24 months (p<0.0001) during MMTT. NEFA in KPDM-ins decreased over 
      30-120 minutes (p<0.05), but not in KPDM+ins. Overall, C3 was higher in KPDM-ins 
      vs KPDM+ins at 12 months (p = 0.0081) and 24 months (p = 0.0019), while ASP was 
      lower at baseline (p = 0.0024) and 12 months (p = 0.0281), with a decrease in 
      ASP/C3 ratio. CONCLUSIONS: Notwithstanding greater adiposity in KPDM-ins, greater 
      NEFA decreases and lower ASP levels during MMTT suggest better insulin and ASP 
      sensitivity in these patients.
FAU - Liu, Yan
AU  - Liu Y
AD  - Centre de Recherche de l'Institut Universitaire de Cardiologie & Pneumologie de 
      Quebec, Universite Laval, Quebec, Canada; Department of Pediatrics, Tongji 
      Hospital, HuaZhong University of Science and Technology, Wuhan, Hubei, P. R. 
      China.
FAU - Gupta, Priyanka
AU  - Gupta P
AD  - Centre de Recherche de l'Institut Universitaire de Cardiologie & Pneumologie de 
      Quebec, Universite Laval, Quebec, Canada.
FAU - Lapointe, Marc
AU  - Lapointe M
AD  - Centre de Recherche de l'Institut Universitaire de Cardiologie & Pneumologie de 
      Quebec, Universite Laval, Quebec, Canada.
FAU - Yotsapon, Thewjitcharoen
AU  - Yotsapon T
AD  - Division of Endocrinology and Metabolism, Department of Medicine, Faculty of 
      Medicine, Chulalongkorn University, Bangkok, Thailand.
FAU - Sarat, Sunthornyothin
AU  - Sarat S
AD  - Division of Endocrinology and Metabolism, Department of Medicine, Faculty of 
      Medicine, Chulalongkorn University, Bangkok, Thailand.
FAU - Cianflone, Katherine
AU  - Cianflone K
AD  - Centre de Recherche de l'Institut Universitaire de Cardiologie & Pneumologie de 
      Quebec, Universite Laval, Quebec, Canada.
LA  - eng
GR  - Canadian Institutes of Health Research/Canada
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20141002
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 0 (Adipokines)
RN  - 0 (Fatty Acids, Nonesterified)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Insulin)
RN  - 0 (Triglycerides)
RN  - 0 (complement C3a, des-Arg-(77)-)
RN  - 80295-42-7 (Complement C3a)
SB  - IM
MH  - Adipokines/blood
MH  - Adiposity
MH  - Adolescent
MH  - Adult
MH  - Complement C3a/analysis/*metabolism
MH  - Diabetes Mellitus, Type 1/blood/drug therapy/*metabolism
MH  - Diabetic Ketoacidosis/blood/drug therapy/*metabolism
MH  - Fatty Acids, Nonesterified/blood/metabolism
MH  - Female
MH  - Humans
MH  - Hypoglycemic Agents/therapeutic use
MH  - Insulin/therapeutic use
MH  - *Lipid Metabolism
MH  - Male
MH  - Middle Aged
MH  - Postprandial Period
MH  - Triglycerides/blood/metabolism
MH  - Young Adult
PMC - PMC4183552
COIS- Competing Interests: This study was partly funded by a Diabetes Research Grant 
      from The Endocrine Society of Thailand (sponsored by GlaxoSmithKline). There are 
      no patents, products in development or marketed products to declare. This does 
      not alter the authors' adherence to all the PLOS ONE policies on sharing data and 
      materials, as detailed online in the guide for authors.
EDAT- 2014/10/03 06:00
MHDA- 2015/12/23 06:00
PMCR- 2014/10/02
CRDT- 2014/10/03 06:00
PHST- 2014/05/26 00:00 [received]
PHST- 2014/09/03 00:00 [accepted]
PHST- 2014/10/03 06:00 [entrez]
PHST- 2014/10/03 06:00 [pubmed]
PHST- 2015/12/23 06:00 [medline]
PHST- 2014/10/02 00:00 [pmc-release]
AID - PONE-D-14-22743 [pii]
AID - 10.1371/journal.pone.0109237 [doi]
PST - epublish
SO  - PLoS One. 2014 Oct 2;9(10):e109237. doi: 10.1371/journal.pone.0109237. 
      eCollection 2014.